This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Betamethasone valerate transdermal medicated plaster


Medicated plaster formulation of betamethasone valerate.

Drugs List

  • betamethasone 2.25mg medicated plaster
  • BETESIL 2.25mg medicated plaster
  • Therapeutic Indications


    Inflammatory skin conditions unresponsive to less potent corticosteroids
    Plaque psoriasis



    Apply 1 medicated plaster to the skin area to be treated once daily.

    The maximum daily dose is 6 medicated plasters (wait at least 30 minutes between one application and the next) and the maximum treatment period should not exceed 30 days.


    Children under 18 years
    Acne vulgaris
    Exudative dermatosis
    Perioral dermatitis
    Skin infection
    Skin manifestation of tuberculosis
    Skin ulcer

    Precautions and Warnings


    Careful supervision of patients with psoriasis required
    Contains hydroxybenzoate
    Avoid occlusive dressings
    Cleanse and dry skin before application
    Do not apply on or near breasts
    Not to be applied to the face
    Prolonged use may cause atrophic skin changes
    Prolonged/excessive use may lead to adrenal suppression
    Risk of generalised pustular psoriasis with use of topical corticosteroids
    Withdraw gradually after long-term use
    Withdraw gradually if adrenal suppression suspected
    Discontinue if hypersensitivity reactions occur

    Pregnancy and Lactation


    Use betamethasone valerate medicated plaster with caution during pregnancy.

    The manufacturer notes that this medication should only be considered if the expected benefit to the mother is greater than any risk to the foetus, also taking into account the evaluation of the treatment period and the size of the skin area to be treated.

    Topical steroids must not be used on large areas of skin or for long periods of time during pregnancy. Topical administration of corticosteroids in pregnant laboratory animals may result in the impairment of foetal development.


    Use betamethasone valerate medicated plaster with caution during breastfeeding.

    The manufacturer notes that this medication should only be considered if the expected benefit to the mother is greater than any risk to the breastfed infant.

    Although it is not known if topical corticosteroids are excreted in human milk, systemic corticosteroids are excreted.


    After application of plaster, do not allow skin to come in contact with water.

    If edges of plaster start to lift, apply adhesive strips to secure.

    Side Effects

    Cushing's syndrome
    Formation of pustules
    Skin atrophy
    Suppression of the hypothalamic-pituitary-adrenal axis


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.